Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEVPRO-1: mevrometostat plus enzalutamide versus enzalutamide or docetaxel in metastatic castration-resistant prostate cancer after abiraterone
2024-511650-50-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of mevrometostat in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Pfizer. Primary endpoint: Radiographic progression-free survival. Planned start Jan 2025; status: authorised.
02
Drugs
mevrometostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2024-511650-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511650-50-00.